180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 33,500 shares, an increase of 29.3% from the February 13th total of 25,900 shares. Approximately 2.4% of the shares of the stock are short sold. Based on an average daily volume of 410,200 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Friday, March 7th.
Check Out Our Latest Research Report on ATNF
180 Life Sciences Price Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC acquired a new position in 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned 2.20% of 180 Life Sciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 4.07% of the company’s stock.
180 Life Sciences Company Profile
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
Further Reading
- Five stocks we like better than 180 Life Sciences
- What is the Dow Jones Industrial Average (DJIA)?
- How to Build the Ultimate Everything ETF Portfolio
- How Investors Can Find the Best Cheap Dividend Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- When to Sell a Stock for Profit or Loss
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.